# Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

> **NCT02101164** · PHASE4 · WITHDRAWN · sponsor: **Amgen**

## Conditions studied

- Solid Tumor
- Metastatic Bone Disease

## Interventions

- **BIOLOGICAL:** denosumab
- **DRUG:** pamidronate

## Key facts

- **NCT ID:** NCT02101164
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-11
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101164, "Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02101164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*